ENANTA PHARMACEUTICALS, INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ENANTA PHARMACEUTICALS, INC (ENTA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -1.50% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2025 was -1.50%.
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was -0.70%.
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was -0.90%.
- ENANTA PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was -1.50%, a 287.50% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2025-09-30 | -1.50% 10-K · filed 2025-11-19 | |
| 2024-09-30 | -0.70% 10-K · filed 2025-11-19 | |
| 2023-09-30 | -0.90% 10-K · filed 2025-11-19 | 0.90% 10-K · filed 2023-11-22 |
| 2022-09-30 | -1.50% 10-K · filed 2024-11-27 | 1.50% 10-K · filed 2022-11-23 |
| 2021-09-30 | 0.80% 10-K · filed 2023-11-22 | |
| 2020-09-30 | 2.60% 10-K · filed 2022-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |